Pooja Shah, MD
Dermatology · Huntington, NYNPI 1003201179
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,692 of the $13,381 with a category attached, or 79.9%. Incyte Corporation accounts for 68.3% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $12,809, more than ten times the $37 reported in 2021.
Across 29 payments — averaging $461.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$9K
- Sanofi$4K
- Johnson & Johnson$183
- E.r. Squibb & Sons, L.L.C.$150
- AbbVie$128
- Sun Pharmaceutical Industries Inc.$95
- plus $166 from 5 others
What the payments were for
- Consulting fees$10,69280%
- Travel & lodging$1,52911%
- Food & beverage$1,0958%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 10 | $9,137 |
| Sanofi | 6 | $3,522 |
| Johnson & Johnson | 2 | $183 |
| E.r. Squibb & Sons, L.L.C. | 2 | $150 |
| AbbVie | 3 | $128 |
| Sun Pharmaceutical Industries Inc. | 1 | $95 |
| LEO Pharma Inc. | 1 | $48 |
| Novartis | 1 | $43 |
| Stryker | 1 | $37 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| Smith+Nephew | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,381 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $59,539 |
| Tacrolimus | 57 | $14,330 |
| Ketoconazole | 333 | $6,817 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 60 | $3,323 |
| Clobetasol Propionate | 87 | $3,119 |
| Tretinoin | 43 | $2,477 |
| Ammonium Lactate | 102 | $2,278 |
| Metronidazole | 28 | $1,602 |
| Triamcinolone Acetonide | 134 | $1,549 |
| Mometasone Furoate | 54 | $1,439 |
| Ciclopirox | 20 | $1,344 |
| Clindamycin Phosphate | 35 | $1,277 |
| Doxycycline Hyclate | 32 | $1,050 |
| Halobetasol Propionate | 21 | $1,031 |
| Mycophenolate Mofetil | 12 | $671 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Huntington
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.